SCHEDULE: Westlake BioPartners Amends Kyverna Therapeutics Stake
Beneficial Ownership Report
Westlake BioPartners entities and Dr. Beth C. Seidenberg filed an amended Schedule 13G for Kyverna Therapeutics, Inc., reporting a combined 7.8% beneficial ownership.
Summary
- Westlake BioPartners entities and Dr. Beth C. Seidenberg filed an Amendment No. 1 to Schedule 13G for Kyverna Therapeutics, Inc. common stock.
- Dr. Beth C. Seidenberg is deemed to beneficially own an aggregate of 4,657,257 shares, representing 7.8% of the class.
- Westlake BioPartners Fund I, L.P. beneficially owns 3,787,940 shares, representing 6.3% of the class.
- Westlake BioPartners Opportunity Fund I, L.P. beneficially owns 869,317 shares, representing 1.5% of the class.
- Westlake BioPartners GP I, LLC and Westlake BioPartners Opportunity GP I, LLC are general partners of the respective funds and are also reporting persons.
- Dr. Sean E. Harper is no longer a managing director of Westlake GP I and Westlake Opportunity GP I and is therefore no longer a Reporting Person on this amendment.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership structure and internal management changes within the reporting investment entities, with no direct positive or negative implications for Kyverna Therapeutics' operational or financial performance.
Risks
- Each Reporting Person disclaims beneficial ownership of the shares of Common Stock, except to the extent of their pecuniary interest therein, or for shares held of record.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Kyverna Therapeutics, Inc.'s future performance or operations.
Industry Context
StockSavvy.ai notes that Schedule 13G filings provide transparency into significant institutional and individual ownership stakes, which can influence corporate governance and strategic direction. For a biotechnology company like Kyverna Therapeutics, a stable and substantial institutional investor base, even with internal changes at the fund level, can be viewed positively for long-term stability.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Director of Westlake GP I and Westlake Opportunity GP I | Dr. Sean E. Harper | N/A | N/A | No longer a managing director of the general partners and thus no longer a Reporting Person. |
Related Party Transactions
- Under certain circumstances, the general and limited partners or members of Westlake BioPartners Fund I, L.P., Westlake BioPartners Opportunity Fund I, L.P., Westlake BioPartners GP I, LLC, and Westlake BioPartners Opportunity GP I, LLC may be deemed to have the right to receive dividends from, or proceeds from the sale of, Kyverna Therapeutics securities owned by these entities.
Stakeholder Impact
- Shareholders: Provides updated transparency on significant institutional ownership and changes in reporting persons associated with those holdings.
Key Dates
| Date | Description |
|---|---|
| 2024-02-06 | Date of Power of Attorney for Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC. |
| 2024-02-06 | Date of Power of Attorney for Westlake BioPartners Opportunity Fund I, L.P. and Westlake BioPartners Opportunity GP I, LLC. |
| 2024-11-08 | Date of Joint Filing Agreement. |
| 2025-12-31 | Date of event requiring the filing of this statement (end of reporting period for beneficial ownership). |
| 2026-02-05 | Signature date for the Schedule 13G Amendment No. 1. |
Recommendation
holdThis filing is an informational update regarding beneficial ownership and internal management changes within the Westlake BioPartners entities. It does not contain new financial or operational data for Kyverna Therapeutics that would warrant a change in investment stance. The significant ownership stake maintained by Dr. Beth C. Seidenberg and the Westlake funds suggests continued confidence, but the filing itself offers no new catalysts for a 'buy' or 'sell' recommendation.
Keywords
Kyverna Therapeutics, Westlake BioPartners, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.